{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:36:55Z","timestamp":1783921015454,"version":"3.55.0"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SAR439459 (SAR'459), a \u201csecond\u2010generation\u201d human anti\u2010transforming growth factor beta (TGF\u03b2) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I\/Ib study, we evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of SAR'459\u2009\u00b1\u2009cemiplimab (intravenous) in patients with advanced solid tumors. Increasing doses of SAR'459 were administered every 2 or 3\u2009weeks (Q2W, Q3W) alone (Part 1A) or with 3\u2009mg\/kg cemiplimab Q2W or 350\u2009mg Q3W (Part 1B). In Part 2A (dose expansion), melanoma patients were randomly (1:1) administered 22.5 or 7.5\u2009mg\/kg SAR'459. In Part 2B (dose expansion), 22.5\u2009mg\/kg SAR'459 and 350\u2009mg cemiplimab Q3W were administered. The primary end points were maximum tolerated dose (MTD) or maximum administered dose (MAD; Part 1), preliminary antitumor activity (Part 2B), and optimal monotherapy dose (Part 2A). Twenty\u2010eight and 24 patients were treated in Parts 1A and 1B, respectively; MTD was not reached, MAD was 15 (Q2W) and 22.5\u2009mg\/kg (Q3W) alone and in combination, respectively. Fourteen and 95 patients, including 14 hepatocellular carcinoma (HCC) patients, were treated in Parts 2A and 2B, respectively. The population PK model yielded satisfactory goodness\u2010of\u2010fit plots and adequately described the observed data by a two\u2010compartment PK model with linear elimination. Objective responses were not observed in Parts 1 and 2A. In Part 2B, objective response rate was 8.4% and 7.1% across tumor types and the HCC cohort, respectively. The most frequent treatment\u2010emergent adverse effects were hemorrhagic events (43.5%), keratoacanthoma (6.8%), and skin neoplasms (6.2%). Fatal bleeding occurred in 21.4% HCC patients despite the implementation of mitigation measures. SAR'459 monotherapy and combination with cemiplimab appeared relatively safe and tolerable in limited number of patients in dose escalation. However, the study was discontinued due to the unclear efficacy of SAR'459 and bleeding risk, particularly in HCC patients.<\/jats:p>","DOI":"10.1111\/cts.13854","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T04:35:00Z","timestamp":1718858100000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGF\u03b2 inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1\/1b study"],"prefix":"10.1111","volume":"17","author":[{"given":"Joaquina C.","family":"Baranda","sequence":"first","affiliation":[{"name":"Department of Internal Medicine University of Kansas Cancer Center  Fairway Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Robbrecht","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Doger","sequence":"additional","affiliation":[{"name":"START Madrid Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Humanitas University Via Rita Levi Montalcini  Pieve Emanuele, Milan Italy"},{"name":"IRCCS Humanitas Research Hospital\u2010Humanitas Cancer Center Via Manzoni  Rozzano, Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Barve","sequence":"additional","affiliation":[{"name":"Mary Crowley Cancer Research  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Jacques","family":"Grob","sequence":"additional","affiliation":[{"name":"Aix Marseille University, H\u00f4pital de la Timone  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0667-3284","authenticated-orcid":false,"given":"Oliver","family":"Bechter","sequence":"additional","affiliation":[{"name":"Department of General Medical Oncology Leuven Cancer Institute University Hospitals Leuven, KU Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vieito","sequence":"additional","affiliation":[{"name":"Vall d'Hebron University Hospital and Institute of Oncology (VHIO) Spain  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"de Miguel","sequence":"additional","affiliation":[{"name":"START\u2010CIOCC HM Sanchinarro  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"University of Essen and the German Cancer Consortium  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology, PLCC  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemence","family":"Pouzin","sequence":"additional","affiliation":[{"name":"Sanofi  Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-5362","authenticated-orcid":false,"given":"Cathy","family":"Cantalloube","sequence":"additional","affiliation":[{"name":"Sanofi  Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Chen","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Demers","sequence":"additional","affiliation":[{"name":"Sanofi  Vitry\u2010sur\u2010Seine France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amele","family":"Amrate","sequence":"additional","affiliation":[{"name":"Sanofi  Vitry\u2010sur\u2010Seine France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Abbadessa","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Center for Immuno\u2010Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01053-x"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32339"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25492"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1811605"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","unstructured":"WilliamsonS HodiSF JohnsonM et\u00a0al.Safety Pharmacokinetic and Pharmacodynamic Results from Dose Escalation of SAR439459 a TGF\u03b2 Inhibitor as Monotherapy or in Combination with Cemiplimab in a Phase 1\/1b Study. Poster presented at: The ASCO Annual Meeting; Chicago IL USA.2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.2510"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.520"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1349589"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0192-4"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac253"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1653-0"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090353"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-2653"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1342"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001395"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04468-6"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00521-1"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfaa024"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.23.4823"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab058"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000664"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.003"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2013.0466"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T02:15:15Z","timestamp":1719972915000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/cts.13854"],"URL":"https:\/\/doi.org\/10.1111\/cts.13854","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"2024-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13854"}}